Homepage
Medication Guide
What Are the Purchase Channels for Mobocertinib (Exkivity)?
Mobocertinib (Exkivity) is a targeted drug used for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. With its increasingly widespread clinical applic...
506
Monday, December 15th, 2025, 14:20
What Are the Precautions for Valcyte (valganciclovir) Administration?
Valcyte (valganciclovir) is an important antiviral medication that plays a key role in the treatment of cytomegalovirus (CMV) retinitis and the prevention of post-transplant CMV disease.What Are the P...
506
Monday, December 15th, 2025, 14:04
What Are the Purchasing Channels for Valcyte?
Valcyte (valganciclovir) is a key antiviral drug for the treatment and prevention of Cytomegalovirus (CMV) infections. It plays a vital role in treating CMV retinitis in AIDS patients and preventing C...
506
Monday, December 15th, 2025, 13:30
Adverse Reactions of Lorlatinib (Lorviqua)
Lorlatinib (Lorviqua) is a targeted therapy for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). By inhibiting the abnormal activity of ALK kinase, this...
512
Monday, December 15th, 2025, 13:27
Dosage and Administration, Recommended Dose of Lorlatinib (Lorviqua)
Lorlatinib (Lorviqua) is a third-generation ALK inhibitor that provides an important treatment option for patients with ALK-positive non-small cell lung cancer (NSCLC).Dosage and Administration, Recom...
508
Monday, December 15th, 2025, 13:23
What Are the Indications for Lorlatinib (Lorviqua)?
Lorlatinib (Lorviqua) is an oral kinase inhibitor primarily indicated for the treatment of specific types of non-small cell lung cancer (NSCLC). By inhibiting the abnormal activity of the ALK gene in ...
507
Monday, December 15th, 2025, 13:17
What Are the Purchase Channels for Lorlatinib (Lorviqua)?
Lorlatinib (Lorviqua) is a third-generation dual-target inhibitor of ALK/ROS1 and has become an important treatment option for patients with ALK-positive non-small cell lung cancer (NSCLC).What Are th...
506
Monday, December 15th, 2025, 13:10
Dosage and Administration, Recommended Dose of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation.Dosage and Administ...
510
Monday, December 15th, 2025, 09:47
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET kinase inhibitor targeting specific gene mutations, developed by Novartis and approved for marketing by the U.S. FDA in 2020.What Are the Indications fo...
507
Monday, December 15th, 2025, 09:41
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation, offering a new treatment option for patients with this specific geneti...
506
Monday, December 15th, 2025, 09:34
28 / 207
2063 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved